Quantum-Si Announces Presentation on the Use of Next-Generation Protein Sequencing™ to Detect Disease-Relevant Proteoforms at the Festival of Genomics and Biodata
10 Junho 2024 - 10:00AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced a
presentation by Gloria Sheynkman, Ph.D., Assistant Professor in the
Department of Molecular Physiology and Biological Physics at the
University of Virginia at the Festival of Genomics and Biodata
conference being held in Boston on June 12-13, 2024.
The presentation, titled “Next Generation Proteomics to Detect
Disease-Relevant Proteoforms” will be on Wednesday, June 12th at
2:50 p.m. on the Omics Stage and will describe the application of
Quantum-Si’s Next-Generation Protein Sequencing (“NGPS”) to
identify protein variants that have a role in complex disease.
Dr. Sheynkman and her team at the University of Virginia are
using advanced analytical and computational approaches to identify
and understand how proteomic variation underlies human disease and
to capture alternative splicing variants. They are developing
approaches to discover novel disease proteoforms, assay
proteoform-specific functions, and elucidate the molecular
mechanisms by which proteoforms rewire cellular networks to drive
disease states.
NGPS is a complementary, powerful technology that reveals
proteoforms that are difficult to distinguish with antibodies and
sometimes mass spectrometry. The Quantum-Si platform uses
dye-labeled amino acid recognizers to distinguish subtle amino acid
variations in isoform-specific peptides, generating new proteoform
insights related to human health and disease.
In this presentation, Dr. Sheynkman will describe creation of a
database for long-read-guided interpretation of protein isoforms
and construction of a map of protein isoforms for splicing events
associated with bone mineral density in the human fetal osteoblast
(hFOB) cell line. Using this approach the lab derived a list of
actin-binding tropomyosin (TPM1/2)-informative peptides and TPM2
isoform-informative peptides from their long-read transcript
database, then utilized the Quantum-Si Platinum® instrument to
differentiate synthetic peptides that correspond to TPM1/2 paralogs
and spliceoforms. Overall, single molecule sequencing with
orthogonal methods facilitates proteogenomics and the transition
from the discovery to proteoform scoring phase.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at quantum-si.com or
follow us on LinkedIn or X.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240610408438/en/
Investor Contact Jeff Keyes, Chief Financial Officer
ir@quantum-si.com
Media Contact Katherine Atkinson, SVP, Commercial
Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024